Oxytocin mediates atrial natriuretic peptide release and natriuresis after volume expansion in the rat.
Our previous studies have shown that stimulation of the anterior ventral third ventricular region increases atrial natriuretic peptide (ANP) release, whereas lesions of this structure, the median eminence, or removal of the neural lobe of the pituitary block ANP release induced by blood volume expansion (BVE). These results indicate that participation of the central nervous system is crucial in these responses, possibly through mediation by neurohypophysial hormones. In the present research we investigated the possible role of oxytocin, one of the two principal neurohypophysial hormones, in the mediation of ANP release. Oxytocin (1-10 nmol) injected i.p. caused significant, dose-dependent increases in urinary osmolality, natriuresis, and kaliuresis. A delayed antidiuretic effect was also observed. Plasma ANP concentrations increased nearly 4-fold (P < 0.01) 20 min after i.p. oxytocin (10 nmol), but there was no change in plasma ANP values in control rats. When oxytocin (1 or 10 nmol) was injected i.v., it also induced a dose-related increase in plasma ANP at 5 min (P < 0.001). BVE by intra-atrial injection of isotonic saline induced a rapid (5 min postinjection) increase in plasma oxytocin and ANP concentrations and a concomitant decrease in plasma arginine vasopressin concentration. Results were similar with hypertonic volume expansion, except that this induced a transient (5 min) increase in plasma arginine vasopressin. The findings are consistent with the hypothesis that baroreceptor activation of the central nervous system by BVE stimulates the release of oxytocin from the neurohypophysis. This oxytocin then circulates to the right atrium to induce release of ANP, which circulates to the kidney and induces natriuresis and diuresis, which restore body fluid volume to normal levels.
Haanwinckel
M A
MA
Department of Physiology, Federal University of Bahia, Salvador, Brazil.
Elias
L K
LK
Favaretto
A L
AL
Gutkowska
J
J
McCann
S M
SM
Antunes-Rodrigues
J
J
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000378:metabolism*; D001810:Blood Volume; D004231:Diuresis / Q000187:drug effects*; D006982:Hypertonic Solutions; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D008954:Models, Biological; D009318:Natriuresis / Q000187:drug effects*; D010121:Oxytocin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010952:Plasma Substitutes; D011188:Potassium / Q000652:urine; D051381:Rats; D017208:Rats, Wistar; D014667:Vasopressins / Q000097:blood
D006982:Hypertonic Solutions; D010952:Plasma Substitutes; D014667:Vasopressins; D010121:Oxytocin; D009320:Atrial Natriuretic Factor; D011188:Potassium